Epitopea Announces Leadership Transition and New Appointments
Alan C. Rigby Joins as CEO, Jon Moore Transitions to CSO
CAMBRIDGE, UK and MONTREAL, CANADA, 25 July 2024 – Epitopea, a transatlantic RNA immunotherapeutics company and global leader exploiting a new class of untapped tumor-specific antigens, known as CryptigensTM, for the development of off-the-shelf cancer vaccines for difficult to treat cancers announces Dr. Alan C. Rigby as its new Chief Executive Officer (CEO). Alan, a seasoned biotech entrepreneur and oncology innovator takes over the CEO role from Dr. Jon Moore, an Operating Partner with one of Epitopea’s founding investors, Advent Life Sciences. Jon, who has over 20 years’ experience in the pharma and biotech industry, mainly in early-stage discovery and validation, transitions to be Epitopea’s Chief Scientific Officer (CSO). The Company has also expanded its clinical and scientific advisory organization with the addition of Dr. Michael Kalos, an internationally recognized expert in immunotherapy and T cell therapy.
